Articles tagged with Cancer Medication
Researchers analyzed data from large-scale studies of erectile dysfunction medication users and found an overall 11% increase in melanoma risk. However, they attribute the increased risk to detection bias rather than a direct cause-and-effect link between medications and melanoma.
A multi-institutional research team analyzed nearly 11,000 human cancers to identify molecular changes involved in cancer development. They confirmed previously known pathways and discovered new ones, such as IDH1 and VHL, which may be linked to targeted therapy.
A study published in Tobacco Control found that smokers who received customized, frequent emails with quitting tips and social support had higher cessation rates than those who received non-tailored emails or no email support. The success rate was highest among those receiving daily or near-daily guidance.
The FDA approves brigatinib as a second-line therapy for ALK-positive non-small cell lung cancer, demonstrating a 54% response rate and 12.9-month progression-free survival. Brigatinib's longer control duration compared to other next-generation ALK inhibitors suggests its broader spectrum of coverage against resistance mechanisms.
The article explores the benefits and drawbacks of personalized medicine, highlighting concerns over data ownership and access to cancer treatments. It proposes changes within the industry to achieve a more value-based pathway to drug development, prioritizing low- and middle-income countries.
Researchers developed a prototype drug that directly activates a tumor suppressor protein, preventing lung cancer tumors in mice. The study's findings suggest the potential for broad applicability to various human cancers, including breast, prostate, and childhood cancers.
A Phase III clinical trial has shown that an immediate infusion of gemcitabine after bladder cancer tumor removal significantly reduces the risk of cancer recurrence. The study found a 34% reduction in recurrence risk, with no additional side effects compared to a saline infusion.
Researchers discovered that normal cells recognize and attack transformed cells through metabolic changes, including mitochondrial dysfunction and elevated glucose uptake. These changes play a crucial role in eliminating early-stage cancer cells.
Researchers at Michigan Medicine discovered a protein called free C3d that stops cancer's ability to prevent the immune system from destroying cancer cells. The study showed an 80-90% decrease in cancerous tumors, and free C3d has potential as a cancer vaccine and treatment.
Researchers at Massachusetts General Hospital have identified a surprising mechanism for resistance to immune checkpoint blockade, where macrophages rapidly remove drugs from T cells. The study suggests that targeting macrophages could improve treatment efficacy in patients.
A clinical trial funded by the National Eye Institute shows that monthly eye injections of Avastin improve visual acuity on average from 20/100 to 20/40, comparable to Eylea. Macular edema decreased significantly in both groups, with higher resolution rates in the Eylea group.
Recent studies identified targeted therapies that improved benefits for patients with pancreatic cancer, including one with an ALK gene mutation. The assessment of actionable alterations is now part of routine care at UPMC.
Dr. Daniel Von Hoff, a world-renowned expert in cancer therapies, is honored by Columbia University with a gold medal for his outstanding accomplishments in clinical medicine. This recognition marks the 250th anniversary of P&S, one of the nation's most accomplished medical schools.
A Rutgers University study suggests that lithium, used to treat bipolar disorder, may prevent brain cell damage and stop the chemical glutamate from sending signals to other cells. The research found that lithium and rapamycin protected nerve cells in the brain and stopped further brain cell damage.
Researchers found that platelets release TGF-beta to suppress T cells and promote immune tolerance to certain cancers. Adding antiplatelet drugs like aspirin may improve adoptive T cell therapy against melanoma and other cancers.
A large data set has revealed genetic variations that are more common in black women with breast cancer, which could lead to more personalized risk assessments and improved treatment outcomes. The study also found that black women were more likely to develop aggressive breast cancer subtypes.
A new blood test can detect multiple copies of the androgen receptor gene in men with advanced prostate cancer, indicating a lower likelihood of responding to targeted treatments. The test could help doctors personalize treatment options for patients.
Recent studies by TGen and UNC Lineberger researchers provide insight into glioblastoma's evolution and how to combat this aggressive brain tumor. The studies reveal that mutations affect how cancer starts and evolves, while combining drugs targeting PI3K and MAPK pathways show promise as a therapeutic approach.
A commentary and editorial in Reproductive BioMedicine Online argue that a registry of egg donors is needed to monitor long-term health risks, citing five case histories of women who developed breast cancer after donation. The authors highlight the lack of data on this topic and call for increased transparency about potential risks.
Researchers at the University of Texas MD Anderson Cancer Center used TACC's advanced computers to discover a potential new cancer drug, mebendazole, which can selectively inhibit TNIK enzyme activity. Virtual screening and molecular modeling approaches identified this compound as a strong candidate for further exploration.
Researchers used CRISPR genome editing technology to target unique DNA sequences formed by fusion genes, cutting out mutated DNA and replacing it with a gene that leads to cancer cell death. This approach improved survival rates in mouse models of aggressive liver and prostate cancers.
The WorldQuant Initiative combines advanced molecular profiling technologies with quantitative methods to analyze genomic data, enabling the prediction of disease risk and outcomes. Researchers will leverage predictive tools to improve diagnosis and treatment for various illnesses.
Researchers will test drug Selumetinib on patients after endoscopic removal of stage I gastric cancer. The goal is to reverse pre-cancerous metaplasia and prevent cancer recurrence.
A study found that only 18 out of 47 cancer indications approved by the NHS Cancer Drugs Fund showed statistically significant benefits, with a median overall survival benefit of 3.2 months. The majority of drugs failed to show meaningful clinical benefits when considering quality of life and toxic side effects.
Researchers from the University of Leicester and University Hospitals of Leicester NHS Trust have reported outstanding results from a long-term follow-up study on patients with CLL. The study, which used a selective BTK inhibitor, showed durable remissions without new toxicities in most patients.
Researchers link cancer's high mutation rate to an ancient stress response mechanism used by single-celled organisms. The discovery sheds new light on the evolution of cancer genes and may lead to novel therapeutic approaches.
Pharmacoscopy enables fast and accurate analysis of immune cell interactions, identifying previously unknown immunomodulatory effects of approved drugs. The technique has the potential to revolutionize personalized medicine by visualizing individual patient responses to various drugs.
A recent study by University of Missouri researchers has found that gallbladder cancer rates are decreasing in men, but not in women. The study also revealed a rising trend of late-stage diagnoses. Patients who received both surgical and radiation treatment experienced the highest survival rates.
Researchers found that patients with increased PD-1+ CD8 T cells in their blood after starting treatment experienced better clinical outcomes. The study's results suggest that monitoring activated T cells may help oncologists and patients decide whether to continue or combine treatments.
Researchers developed a laboratory technique to test the effectiveness of treatments for breast cancer metastases in bone, mimicking interactions between cancer cells and bone cells. The 'bone-in culture array' model found that danusertib inhibits bone metastasis while other drugs stimulate growth of slow-growing cancer cells.
Researchers have developed a malaria protein-based drug that demonstrates promising results against chemotherapy-resistant bladder cancer. The new treatment showed a dramatic response to the malaria drug combo, resulting in an 80% survival rate among treated animals.
Researchers at Duke-NUS Medical School and Genome Institute of Singapore have identified altered promoters in gastric cancer that change gene expression profiles, enabling tumors to evade the immune system. The study's findings may lead to new approaches for cancer immunotherapy treatment.
Researchers found that SLAMF7 is essential for immune cells to target cancer cells, leading to a potential breakthrough in precision medicine. The discovery could help predict which patients will respond to CD47 inhibitors and improve the effectiveness of immunotherapy.
Scientists are developing novel molecules to target RAS, a common driving mutation in pancreatic and lung cancer. The collaboration aims to create gold standard tests for analyzing these inhibitors.
Researchers are exploring immune cells that normally help the body but can hinder chemotherapy's effectiveness. By understanding how these cells interact, scientists hope to create targeted therapies to preserve chemotherapy's benefits while minimizing unwanted side effects.
Researchers created a time-lapse animation of the concentrative nucleoside transporter (CNT) transporting nucleosides into cells. The study provides important structural information for designing smarter, more specific anticancer and antiviral drugs.
A new study found that language barriers, information overload, and cultural differences disadvantage some Latina breast cancer patients. However, no significant inequities were recorded in how doctors provide information. The research highlights the need for providers to be more culturally sensitive and patient-centered.
Researchers discovered a protein signature that predicts leukemia, which could lead to novel treatments. The activation of STAT5 causes competition among proteins, leading to acute lymphoblastic leukemia.
Despite narrowing global inequalities in childhood leukemia survival, persistent disparities remain, with five-year survival rates varying widely between countries. The study highlights the need for improved access to efficient treatment and care for children with leukemia, particularly in low- and middle-income countries.
Researchers have developed a method to predict interactions among multiple drugs in combination, bypassing the need for astronomical measurements. The new mathematical model enables scientists to identify optimal blends for chemotherapy cocktails and potentially aid personalized medicine.
A new article evaluates the Oregon Death with Dignity Act, finding 64% of patients who used lethal medication had cancer. The study also reveals an increase in prescriptions written annually from 24 to 218 between 1998 and 2015.
A study published in JAMA Oncology analyzes 18 years of data on Oregon's Death with Dignity Act, revealing that 64% of patients who used the law ingested the medication and died. The majority of users were older white men with college education, and cancer was the underlying terminal illness for 77% of cases.
A clinical trial found that 13% of patients with high PSA levels after initial hormone therapy showed strong responses to abiraterone acetate, with 5 full responders and partial benefits in 33% of cases.
Researchers at the University of Missouri have discovered a new biomarker, TSPYL5, that can help identify prostate cancer progression and predict treatment response. The testis-specific protein varied between normal patients and tumor tissues with different Gleason scores, allowing clinicians to make rational decisions in treating the ...
A Yale researcher found that the FDA reviews and approves new medicines in a shorter timeframe than its peer agency in Europe. The study compared review times for new drugs approved by the FDA and EMA between 2011 and 2015, classifying them by therapeutic areas and 'orphan' drugs.
Researchers used supercomputers to simulate the behavior of K-Ras protein in cell membranes, discovering that certain lipids can turn the protein 'off' by changing its orientation. This finding suggests limiting concentrations of PIP2 in cell membranes could help prevent cancer progression.
Researchers have found a way to deliver cancer drugs to hypoxic regions of solid tumors, making them more susceptible to treatment. The new delivery system, using liposomes to carry prodrugs, has shown promising results in treating non-small cell lung cancer.
A combination of two drugs targeting molecular pathways controlled by the RAS gene has shown promise in treating RAS-driven lung, ovarian, and thyroid cancers. Patients with heavily treated cancers have experienced long-term clinical benefit from the treatment, including one patient on treatment for over two years.
Researchers have developed a new humanized mouse model of colorectal cancer, allowing them to test immunotherapies and potential combination treatments. The model has shown promise in preclinical studies, including the successful activation of the immune system against cancer cells.
A clinical trial of nivolumab found that 16% of patients with advanced nonsmall cell lung cancer survived at least five years, significantly higher than the standard 1-4% survival rate. Researchers hope to identify specific genetic markers linked to long-term response.
A team led by Jennifer Wargo at MD Anderson is studying the connection between gut bacteria and immune system response in melanoma patients treated with anti-PD1 therapy. The study aims to understand how microbiome diversity influences treatment outcomes.
The Case Comprehensive Cancer Center has been named to a new national colorectal cancer dream team, comprising scientists and clinicians from top institutions. The team will test a promising new therapy for the first time in human patients, combining glutaminase inhibitor CB-839 with chemotherapy medication capecitabine.
A new study found that continuing checkpoint inhibitor treatment after tumor growth can significantly extend survival for some head and neck cancer patients. The research, based on a phase 3 clinical trial, showed that 57 of 139 patients who continued treatment had a median survival period of 12.7 months.
Researchers develop new technologies to precisely measure protein levels serving as tumor markers for personalized cancer treatment. This approach aims to predict tumor response to cancer therapeutics and match patients with the right drug.
Researchers identified new genes associated with ultra-rare disease Erdheim-Chester disease, which affects multiple organs, and found connections to various types of cancer. The discovery may lead to improved diagnosis and new treatments for this rare condition.
Researchers at UAB have designed triple-threat cancer-fighting polymer capsules that can deliver drugs to tumors while protecting against collateral damage. The capsules show good imaging contrast, stably encapsulate cancer drugs, and can be triggered by low- or high-power ultrasound to release their cargo.
Scientists have discovered a synergistic effect between an anticancer and an antirheumatic drug, improving the former's ability to kill off cancer cells. The combination works by interacting with the cell's DNA, disrupting normal function and causing cell death.
A study led by Raffaella Sordella proposes a novel theory on how cancers circumvent targeted therapy killing power. The research suggests that genetic diversity in tumor cells, caused by non-genetic mechanisms, can help them survive and eventually relapse.
A recent study conducted by the University of Calgary found that radon gas levels in over 2,300 Calgary and area homes exceeded Health Canada's acceptable limits. The results show that there is no unaffected neighborhood, and homeowners who remediated their homes saw a reduction in radon levels to safe ranges.
The University of Queensland has opened a new imaging facility to study the effects of anti-cancer drugs on human and animal cancers, enabling the development of new treatments. The facility will run Australia's first comparative oncology research program, studying naturally occurring cancers in companion animals.